SpineX

SpineX operates in the medical-device and clinical-trials segment, with a narrower focus on non-invasive spinal neuromodulation than many implantable neurostimulation companies. Its disclosed programs target neurological dysfunction associated with cerebral palsy, spinal cord injury, stroke, multiple sclerosis, traumatic brain injury, and related conditions. SCiP is described as a non-invasive spinal cord neuromodulation device for cerebral palsy, while SCONE™ is being evaluated for functional recovery in paralyzed individuals. This gives SpineX a differentiated clinical use-case orientation: the company is pursuing restoration of bladder, bowel, respiratory, sexual, and sensorimotor functions rather than positioning neuromodulation solely around pain management. The similar-company entries available for comparison repeat SpineX itself rather than naming external peers, so specific competitor claims would be unreliable. Its current market position is therefore best characterized as an early clinical-stage specialist with grant-backed development and a still-unproven path to broad adoption.

SpineX’s trajectory shows a progression from grant-supported technology development toward clinical validation. The company was founded in 2018 and recorded three grants between 2021 and 2023. The earliest disclosed grant, dated Aug 19, 2021, totaled $255,568 and was led by the National Science Foundation. A Jun 28, 2022 announcement marked enrollment of the first patient in a spinal neuromodulation trial, followed by a Jul 21, 2022 grant from the Consortium For Technology & Innovation in Pediatrics. Recruitment was reported as nearly complete on Dec 6, 2023 and closed on Apr 8, 2024, indicating a meaningful execution milestone for the SCONE™ study. On Apr 16, 2025, SpineX reported improved urinary bladder function in paralyzed individuals receiving SCONE™ therapy. Inclusion in the 2025 UCSF Rosenman RISE class further supports continued activity in health innovation. The company remains small, with an employee range of 1–10, and describes itself as a growing clinical-stage medtech business. There is no disclosed follow-on financing, valuation, regulatory clearance, or commercialization data, making clinical translation the key unresolved inflection point.